T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia

Gain-of-function mutations of FLT3 (FLT3-ITD), comprises up to 30% of normal karyotype acute myeloid leukemia (AML) and is associated with an adverse prognosis. Current FLT3 kinase inhibitors have been tested extensively, but have not yet resulted in a survival benefit and novel therapies are awaite...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Alachkar, Houda, Mutonga, Martin, Malnassy, Gregory, Park, Jae-Hyun, Fulton, Noreen, Woods, Alex, Meng, Liping, Kline, Justin, Raca, Gordana, Odenike, Olatoyosi, Takamatsu, Naofumi, Miyamoto, Takashi, Matsuo, Yo, Stock, Wendy, Nakamura, Yusuke
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741775/
https://ncbi.nlm.nih.gov/pubmed/26450903
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados